Skip to content

OptimizeRx Corp

OPRX · XNAS

CIK 1448431fmd_0K0GZNYM01PNANF8BDDNTQ6D3SServices · Services-Business Services, NECTemplate: Standard

Coverage: Jan 01, 2010 to Jun 30, 2026, 65 periods

Income Statement · Annual · Millions · USD
Line itemFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Total revenues81221254361627292109
Cost of revenue––99192623293336
Gross profit461215243639435974
Research and development––020–––00
Selling, general and administrative–––––2833–––
Total operating expenses681219263551697362
Operating income(2)(2)0(4)(2)0(12)(26)(14)12
Interest expense–––––––165
Interest and investment income0000001200
Other non-operating income (expense)000(0)(0)011(6)(5)
Income before taxes(2)(2)0(4)(2)0(11)(25)(19)7
Income tax expense–––(1)–––(8)12
Net income from continuing operations–––(3)–––(18)(20)5
Net income(2)(2)0(3)(2)0(11)(18)(20)5
Net income to common shareholders––0(3)(2)0(11)(18)(20)5
OptimizeRx Corp (OPRX) financial statements · FinancialMD